



Wanjia Group Holdings Limited 萬嘉集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

STOCK CODE: 401



First Quarterly Report 2014/15



WANJIA GROUP
萬嘉集團

HIGHLIGHTS

- The Group has recorded a total turnover of approximately HK\$398.546 million for the three months ended 30 June 2014 as compared to a total turnover of approximately HK\$563.578 million recorded in the corresponding period in year 2013, representing a decrease of approximately 29.28%.
- Gross profit margin of the Group was approximately 9.93% for the three months ended 30 June 2014, compared to the gross profit margin of approximately 8.12% in the corresponding period in year 2013, representing slightly increase of approximately 1.81%.
- The Group has recorded a loss from operations for the three months ended 30 June 2014 of approximately HK\$769.610 million as compared to the profit from operations of approximately HK\$21.355 million recorded in the corresponding period in year 2013. The loss from operation for the current period was mainly contributed to the impairment loss on the full amount of goodwill. By excluding such effect, the Group recorded a profit from operations of approximately HK\$15.873 million in current period. Operating profit margin for the three months ended 30 June 2014 was approximately 3.98% (2013: approximately 3.79%), representing a slight improvement compared to the corresponding period in year 2013.
- The Group has recorded loss attributable to owners of the Company for the three months ended 30 June 2014 of approximately HK\$774.920 million as compared to the profit attributable to owners of the Company of approximately HK\$13.820 million recorded in the corresponding period in 2013.
- The basic and diluted loss per share for the three months ended 30 June 2014 was approximately HK119.51 cents (2013: HK2.13 cents for the basic and diluted earnings per share).
- The directors do not recommend the payment of a dividend for the three months ended 30 June 2014 (2013: Nil).

FIRST QUARTERLY RESULTS (UNAUDITED)

The board of directors (the “**Board**”) of Wanjia Group Holdings Limited (the “**Company**”) is pleased to announce the unaudited condensed consolidated results of the Company and its subsidiaries (collectively, the “**Group**”) for the three months ended 30 June 2014, together with the unaudited comparative figures for the corresponding period in year 2013 as follows:

Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the three months ended 30 June 2014

	Note	Three months ended	
		2014	2013
		HK\$'000	HK\$'000
		(Unaudited)	(Unaudited)
Turnover	3	398,546	563,578
Cost of sales		<u>(358,987)</u>	<u>(517,805)</u>
Gross profit		39,559	45,773
Other income		5,952	2,151
Selling and distribution expenses		(19,924)	(16,237)
Administrative expenses		(9,714)	(10,332)
Impairment loss on goodwill	4	(785,483)	–
(Loss)/profit from operations		(769,610)	21,355
Finance costs		(1,874)	(1,084)
(Loss)/profit before taxation		(771,484)	20,271
Taxation	5	(3,423)	(6,417)
(Loss)/profit for the period		(774,907)	13,854
Other comprehensive (loss)/income for the period, net of tax:			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translating foreign operations		(191)	3,047
Total comprehensive (loss)/income for the period		(775,098)	16,901

		Three months ended	
		30 June	
		2014	2013
		HK\$'000	HK\$'000
	Note	(Unaudited)	(Unaudited)
(Loss)/profit for the period attributable to:			
Owners of the Company		(774,920)	13,820
Non-controlling interests		<u>13</u>	<u>34</u>
		<u>(774,907)</u>	<u>13,854</u>
Total comprehensive (loss)/income for the period attributable to:			
Owners of the Company		(775,112)	16,861
Non-controlling interests		<u>14</u>	<u>40</u>
		<u>(775,098)</u>	<u>16,901</u>
Dividends	6	<u>–</u>	<u>–</u>
(Loss)/earnings per share attributable to owners of the Company			
– Basic	7	<u>HK(119.51) cents</u>	<u>HK2.13 cents</u>
– Diluted	7	<u>HK(119.51) cents</u>	<u>HK2.13 cents</u>

Unaudited Condensed Consolidated Statement of Changes in Equity

For the three months ended 30 June 2014

	Attributable to owners of the Company									
	Share capital HK\$'000 (Note (a))	Share premium HK\$'000 (Note (b))	Other reserve HK\$'000 (Note (c))	Contribution reserve HK\$'000 (Note (d))	Translation reserve HK\$'000	Statutory reserve HK\$'000	(Accumulated losses)/ retained earnings HK\$'000	Sub-total HK\$'000	Non-controlling interests HK\$'000	Total HK\$'000
At 1 April 2013	1	-	-	-	11,471	18,810	102,480	132,762	439	133,201
Profit for the period	-	-	-	-	-	-	13,820	13,820	34	13,854
Other comprehensive income for the period	-	-	-	-	3,041	-	-	3,041	6	3,047
Total comprehensive income for the period	-	-	-	-	3,041	-	13,820	16,861	40	16,901
At 30 June 2013	<u>1</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>14,512</u>	<u>18,810</u>	<u>116,300</u>	<u>149,623</u>	<u>479</u>	<u>150,102</u>
At 1 April 2014	6,484	(7,653)	(6,483)	866,811	15,938	29,128	141,082	1,045,307	416	1,045,723
Loss for the period	-	-	-	-	-	-	(774,920)	(774,920)	13	(774,907)
Other comprehensive (loss)/income for the period	-	-	-	-	(192)	-	-	(192)	1	(191)
Total comprehensive (loss)/income for the period	-	-	-	-	(192)	-	(774,920)	(775,112)	14	(775,098)
Increasing in non-controlling interests resulting from acquisition of subsidiaries	-	-	-	-	-	-	-	-	7,428	7,428
At 30 June 2014	<u>6,484</u>	<u>(7,653)</u>	<u>(6,483)</u>	<u>866,811</u>	<u>15,746</u>	<u>29,128</u>	<u>(633,838)</u>	<u>270,195</u>	<u>7,858</u>	<u>278,053</u>

Notes:

- (a) The share capital of the Group as at 30 June 2013 represents the issued share capital of Luxuriant Expand Global Investments Limited (“**Luxuriant Expand**”) and Timely Hero Enterprises Limited (“**Timely Hero**”) prior to the completion of the corporate reorganisation of the Group (the “**Reorganisation**”) in preparation for the listing of the shares of the Company, details of which are explained under the paragraph headed “Reorganisation” in the section headed “History, development and reorganisation” in the prospectus of the Company dated 30 September 2013 (the “**Listing Document**”). As at 30 June 2014, the share capital of the Group represents the issued share capital of the Company after the completion of Reorganisation.
- (b) The share premium amounted to approximately HK\$7,653,000 represents the capitalised listing expenses arising from the listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 11 October 2013.
- (c) Upon the completion of the reorganisation on 3 September 2013, the amount of approximately HK\$6,483,000 represented the difference between the Company’s share of nominal value of the paid-up capital of the subsidiaries acquired over the Company’s cost of acquisition of the subsidiaries under common control upon the reorganisation as detailed in the prospectus of the Company dated 30 September 2013.
- (d) Contribution reserve represents capitalisation of the outstanding amount of approximately HK\$866,811,000 due from Timely Hero to Hua Xia Healthcare Holdings Limited (“**Hua Xia**”) on 3 September 2013 in consideration of (i) the allotment and issue 1 share of US\$1 in the share capital of Timely Hero to Luxuriant Expand, credited as fully paid up, at the direction of Hua Xia; and (ii) the allotment and issue of a total of 100 shares of US\$1 each in the share capital of Luxuriant Expand, all credited as fully paid up to Hua Xia in consideration of its receipt of 1 share in Timely Hero at the direction of Hua Xia. Details of the reorganisation were set out in the paragraph headed “The Reorganisation” in the section headed “Corporate history, development and Reorganisation” in the prospectus of the Company dated 30 September 2013.

NOTES TO THE CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the three months ended 30 June 2014

1. Corporate Information

The Company was incorporated as an exempted Company with limited liabilities in the Cayman Islands on 9 July 2012. The registered office of the Company is located at Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY1-1111, Cayman Islands and the principal place of business of the Company is located at Room 1902, 19th Floor, No. 101, Kings' Road, Hong Kong.

The principal activity of the Company is investment holding. The Group is principally engaged in pharmaceutical wholesale and distribution and pharmaceutical retail chain business in the People's Republic of China ("PRC").

The Company's shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") since 11 October 2013. The Company's immediate holding company is Greatly Wealth Global Group Limited ("**Greatly Wealth**"), a company incorporated in British Virgin Islands ("**BVI**"). Greatly Wealth is a directly wholly-owned subsidiary of Hua Xia Healthcare Holdings Limited ("**Hua Xia**"), a company incorporated in the Cayman Islands on 28 May 2001 as an exempted company with limited liability, of which are listed on the Growth Enterprise Market ("**GEM**") of the Stock Exchange and it is the ultimate holding company of the Company.

For the purpose of applying the listing of the shares of the Company on the Stock Exchange (the "**Listing**"), the Group underwent the Reorganisation, details of which are explained under the paragraphs headed "Reorganisation" in the section headed "History, development and reorganisation" in the Listing Document.

The condensed consolidated financial statements for the three months ended 30 June 2013 have been prepared as if the Company has been the holding company of the companies now comprising the Group during the period.

The condensed consolidated financial statements are presented in Hong Kong dollars ("**HK\$**"), which is the functional currency of the Company, and the functional currency of most of its subsidiaries is Renminbi ("**RMB**"). The directors of the Company considered that it is more appropriate to present the condensed consolidated financial statements in HK\$ as the shares of the Company are listed on the Main Board of the Stock Exchange. The condensed consolidated financial statements are presented in thousands of units of HK\$ (HK\$'000), unless otherwise stated.

2. Basis of preparation and principal accounting policies

The condensed consolidation financial results for the three months ended 30 June 2014 have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”), which is a collective term includes all applicable HKFRSs, Hong Kong Accounting Standards (“HKASs”) and Interpretations (the “**Interpretations**”) issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance and the applicable disclosure requirements of the Listing Rules of the Stock Exchange (the “**Listing Rules**”). The unaudited condensed consolidated financial results have been prepared under the historical cost except for certain financial assets (including derivative financial instruments) and investment properties that are measured at fair value. Historical cost is generally based on the fair value of the consideration of given in exchange of assets.

The Group has consistently applied its accounting policies to all the periods presented, unless otherwise stated, in the preparation of the condensed consolidated financial statement.

The accounting policies adopted in preparing the unaudited condensed consolidated financial results for the three months ended 30 June 2014 are consistent with those used in the preparation of the annual financial statements for the year ended 31 March 2014 (the “**2013/14 Financial Statements**”), except for the amendments and interpretations of HKFRSs (“**New HKFRSs**”) issued by HKICPA which have become effective in this period as detailed in notes to the 2013/2014 Financial Statements. The directors of the Company believe that the application of the other new and revised standards, amendments or interpretations has no material impact on the condensed consolidated financial results for the period.

3. Turnover

The principal activities of the Group are pharmaceutical wholesales and distribution business and pharmaceutical retail chain business in the PRC. The Group’s turnover represents the net invoiced value of goods sold, after allowances for returns and trade discounts. The turnover for the period is as follows:

	Three months ended 30 June	
	2014	2013
	HK\$’000	HK\$’000
	(Unaudited)	(Unaudited)
Turnover		
Wholesale and distribution of pharmaceutical and related products	339,105	508,293
Retail of pharmaceutical and related products	59,441	55,285
	398,546	563,578

4. Impairment loss on goodwill

The Group has appointed an independent valuer, who is not connected with the Group, to provide the valuation on the recoverable amount of the cash generating units based on the value-in-use calculation. Directors of the Group based on the valuation and recognised an impairment loss on the full amount of goodwill of approximately HK\$785.483 million during the three months ended 30 June 2014.

5. Taxation

No provision for Hong Kong profits tax has been made in the financial statements as the Group had no assessable profits derived from Hong Kong's operation during the period (2013: Nil).

Corporate income tax of approximately 25% has been provided for the profit generated from the pharmaceutical wholesale, distribution and pharmaceutical retail chain businesses in the PRC (2013: approximately 25%).

6. Dividends

The directors of the Company do not recommend the payment of a dividend for the three months ended 30 June 2014 (2013: Nil).

7. (Loss)/earnings per share

The calculation of basic (loss)/earnings per share for the three months ended 30 June 2014 and 2013 was based on the loss for the period attributable to owners of the Company of approximately HK\$774.920 million (2013: profit for the period attributable to owners of the Company of approximately HK\$13.820 million) and on the weighted average number of 648,405,300 shares. (2013: on the assumptions that the proposed 648,405,300 ordinary shares in issue as at the date of listing of the Company's shares on the Stock Exchange were outstanding throughout the entire period for the three months ended 30 June 2013.)

Diluted (loss)/earnings per share were same as the basic (loss)/earnings per share as there were no potential diluted ordinary shares in existence during the three months ended 30 June 2014 and 2013.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review

For the three months ended 30 June 2014 (the “**period under review**”), the Group recorded a turnover on business operations of approximately HK\$398,546 million (2013: approximately HK\$563,578 million), representing decrease of approximately 29.28% as compared to the same period last year. The decrease in turnover was mainly attributable to decrease in revenue generated from the pharmaceutical wholesales segment as a result of the promulgation and implementation of new Good Supply Practice (“**New GSP**”) in Fujian, the People’s Republic of China in April 2014 which imposes stringent regulations on pharmaceutical distributor operation. Under the New GSP, with effect from the year 2016, only selected pharmaceutical distributors are allowed to distribute medicine to the public hospitals and public healthcare institutions. At the beginning of the promulgation of the proposed tightening policy in April 2014, the effect of the New GSP on the medicine distribution industry as well as the effect on the business of Wanjia is uncertain in both short and long term. However, in view of the New GSP, our existing distributor customers have become very prudent in placing the purchase order to our Group and the repayment period for them increase steadily, we therefore prudently tightened the credit policy to the distributor customers gradually during the three months period ended 30 June 2014. As such, the sale to our distributor customer have been decreased by approximately 50% compared to the corresponding period in year 2013.

Gross profit margin of the Group was approximately 9.93% for the three months ended 30 June 2014, compared to the gross profit margin of approximately 8.12% in the corresponding period in year 2013, representing slightly increase of approximately 1.81%.

The Group has recorded a loss from operations for the three months ended 30 June 2014 of approximately HK\$769.610 million as compared to the profit from operations of approximately HK\$21.355 million recorded in the corresponding period in year 2013. The loss from operation for the current period was mainly contributed to the impairment loss on the full amount of goodwill. By excluding such effect, the Group recorded a profit from operations of approximately HK\$15.873 million in current period. Operating profit margin for the three months ended 30 June 2014 was approximately 3.98% (2013: approximately 3.79%), representing a slight improvement compared to the corresponding period in year 2013.

Selling and distribution expenses for the period under review amounted to approximately HK\$19.924 million (2013: approximately HK\$16.237 million), increasing by approximately 22.71% as compared to the same period last year. More selling and distribution expenses incurred mainly attributable to the increase in both salaries and rental expense arising from the increase in both the number of sales and marketing personnel employed by the Group and the number of retail pharmacies during the three months ended 30 June 2014 compared to the corresponding period in year 2013.

Administrative expenses for the period under review amounted to approximately HK\$9.714 million (2013: approximately HK\$10.332 million), decreasing about 5.98%. The decrease in administrative expense mainly due to the corporate administrative expenses incurred by the Group is comparatively less than the amount of corporate administrative service fees charged by Hua Xia Healthcare Holdings Limited, the wholly owned shareholder of the Group, before Wanjia's shares were listed.

In August 2014, Fujian Food and Drug Administration (福建省食品藥品監督管理局) announced the 10 companies which are permitted to conduct the business in the distribution to public hospitals and public healthcare institutions after 2016, in which the operating subsidiary of the Company, namely 福建省福州市惠好藥業有限公司 (Fujian Province Fuzhou City Huihao Pharmaceutical Co. Ltd[#]) is on the list. Notwithstanding this recognition as a qualified participant in the distribution industry is encouraging, the effect of the implementation of the New GSP and any future policy development on the hospital distribution business of the Group remains uncertain. Having taken into account the financial performance as of June 2014, the Board reviewed again the potential effects of the New GSP on the distribution business in late July 2014 and prudently lowered the forecasted performance in sales to distributor customers, therefore, it triggers impairment loss on the goodwill. The carrying amount of goodwill was tested for impairment as at 30 June 2014. The impairment test compared the discounted cash flow of the cash-generating units (CGUs) to the carrying amounts of the CGUs. The recoverable amounts of the CGUs were significantly less than the carrying value of goodwill and impairment loss is recorded in the period under review. During the period under review, the net loss was mainly attributable to the impairment loss on the goodwill of approximately HK\$785.483 million. As a results, the Group reported a loss attributable to owners of the Company of approximately HK\$774.920 million for the three months ended 30 June 2014 (2013: profit attributable to owners of the Company approximately HK\$13.820 million).

Business Review and Outlook

Pharmaceutical wholesale and distribution

The Group has a large and broad customer base through our distribution network in Fujian Province in the PRC. The Group distributes pharmaceutical products to our customers located principally in the Fujian Province and also sells pharmaceutical products in neighboring provinces such as Guangdong, Hunan, Hubei, Jiangxi, Anhui and Zhejiang. Our customers can be categorized into three types namely hospitals and healthcare institutions, distributor customers and end customers such as companies operating pharmaceutical retail chain stores, independent pharmacies, and outpatient departments of community hospitals, healthcare service stations and clinics. The turnover generated from the pharmaceutical wholesale and distribution business for the three months ended 30 June 2014 was approximately HK\$339.105 million (2013: approximately HK\$508.293 million), decreasing by approximately 33.29% as compared to the same period last year. The decrease was mainly attributable to the reduction in sales to distributor customers due to the stringent regulations after the promulgation and implementation of the New GSP.

Pharmaceutical retail chain

The Group operates pharmaceutical retail business through Fujian Huihao Sihai Pharmaceutical Chain Company Limited[#] (福建惠好四海醫藥連鎖有限責任公司) which was accounted for as one of our subsidiaries. The Group offers a wide variety of products in our retail pharmacies including prescription medicines, over-the-counter medicines, healthcare food products, traditional Chinese medicines, medical supplies and medical devices. The Group seeks to introduce new products and services to meet changing customer preferences and to differentiate the Group from our competitors. The turnover generated from pharmaceutical retail chain business for the three months ended 30 June 2014 amounted to approximately HK\$59.441 million (2013: approximately HK\$55.285 million), representing a steady growth of approximately 7.52% compared to the same period last year.

Up to 30 June 2014, 4 new retail pharmacies are being opened in Fujian Province in the PRC. As at 30 June 2014, we directly operated 107 retail pharmacies in six prefectural – level districts of the Fujian Province in the PRC under the brand name “Huihao Sihai”.

[#] *English translations of official Chinese names are for identification purpose only*

Future Prospects

The management of the Group expects that the pharmaceutical market will remain challenging for the rest of 2014. The management has noticed the results of the Group for the three months ended 30 June 2014 was less favorable than the corresponding period in year 2013. Although the challenges remain, the management of the Group will adapt to the changing business environment with effective and efficient measures. We will continue to keep focus on further strengthen the drug delivery to hospitals and expansion the retail pharmacies in the rest of year 2014/15. The management of the Group remains optimistic about the promising pharmaceutical sector in the PRC for the long-run including but not limited to possible future investments in or cooperation with wholesales and distribution companies in PRC and enhances shareholders' returns in the long run.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

Disclosure of Interests

(a) Directors' interest and short position in the securities of the Company and its associated corporations

As at 30 June 2014, the interests and short positions of the directors and chief executive of the Company in the shares of the Company (“**Shares**”), underlying Shares and debentures of the Company or any of its associated corporation (within the meaning of Part XV of the Securities and Futures Ordinance (“**SFO**”)) which will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) contained in the Appendix 10 to the Rules Governing the Listing Rules, were as follows:

(i) *Interests in shares of the Company*

<u>Name of director</u>	<u>Nature of interest</u>	<u>Number of shares</u>	<u>Position</u>	<u>Approximate percentage of the total issued shares</u>
Mr. Weng Jiaying	Personal interest	281,250	Long	0.04%
Mr. Chen Yong	Personal interest	80,000	Long	0.01%

(ii) *Interest in issued share capital of the Company's associated corporation*

<u>Name of director</u>	<u>Name of associated corporation</u>	<u>Capacity/ Nature of interest</u>	<u>Number of shares</u>	<u>Position</u>	<u>Approximate percentage of shareholding in the associated corporation's issued share capital</u>
Mr. Weng Jiaying	Hua Xia (Note 1)	Beneficial interest	1,406,250	Long	0.12%
Mr. Chen Yong	Hua Xia (Note 1)	Beneficial interest	400,000	Long	0.03%

Note 1: Hua Xia Healthcare Holdings Limited (“**Hua Xia**”) held the entire issued share capital of Greatly Wealth Global Group Limited (“**Greatly Wealth**”), a company incorporated in the British Virgin Islands (“**BVI**”) with limited liability, which is in turn interest in 411,917,648 shares of the Company (representing 63.53% of the issued share capital of the Company). Therefore, Hua Xia is an associated corporation of the Company for the purposes of the SFO.

(b) Substantial shareholders' interest and short positions in shares and underlying shares.

As at 30 June 2014, other than the interests of a director or chief executive of the Company as disclosed under the heading "Directors' and chief executive's interest in shares, underlying shares and debentures of the company and its associated corporations" above, the following persons (not being a Director or the chief executive officer of the Company) have an interest or a short position in Shares or underlying Shares which would be required to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of the Group:

(i) Long position in shares of the Company

Name of shareholder	Capacity	Position	Number of shares	Approximate percentage of the total issued shares
Hua Xia (Note 1)	Interested in controlled corporation	Long	411,917,648	63.53%
Greatly Wealth (Note 1)	Beneficial owner	Long	411,917,648	63.53%
Mr. Yung Kwok Leong (Note 2)	Interested in controlled corporation	Long	24,192,100	3.73%
	Beneficial owner	Long	47,009,375	7.25%
Marshal International Investments Limited (Note 2)	Interested in controlled corporation	Long	24,192,100	3.73%

Name of shareholder	Capacity	Position	Number of shares	Approximate percentage of the total issued shares
Easeglory Holdings Limited (Note 2)	Beneficial owner	Long	24,192,100	3.73%
Mrs. Yung Muk Ying (Note 3)	Interest of spouse	Long	71,201,475	10.98%

Notes:

1. Greatly Wealth is a company incorporated in the BVI with limited liability which is wholly and beneficially owned by Hua Xia. By virtue of the SFO, Hua Xia is deemed to be interested in the entire 411,917,648 shares held by the Greatly Wealth.
2. Easeglory Holdings Limited (“**Easeglory**”) is a company incorporated in the BVI with limited liabilities which is wholly and beneficially owned by Marshal International Investments Limited (“**Marshal**”), a company incorporated in the BVI with limited liability and is wholly and beneficially owned by Mr. Yung Kwok Leong (“**Mr. Yung**”). By virtue of the SFO, both Marshal and Mr. Yung are deemed to be interested in the entire 24,192,100 shares held by Easeglory.
3. Mrs. Yung Muk Ying, the spouse of Mr. Yung, is deemed to be interested in 71,201,475 shares held by Mr. Yung in person or through his controlled corporation under the SFO.

(ii) Long position in shares of the associated corporation

Name of associated corporation	Name of registered owner	Capacity	Position	Number of shares in the associated corporation	Approximate percentage of shareholding in the associated corporation's issued share capital
Greatly Wealth	Hua Xia	Beneficial owner	Long	200 shares of US\$1 each	100%

Save as disclosed above, as at 30 June 2014, the directors of the Company were not aware of any other person (other than the directors and chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company under Section 336 of the SFO.

DIRECTOR'S RIGHTS TO ACQUIRE SECURITIES

Apart from as disclosed under the heading "Directors' and chief executive's interests in shares, underlying shared and debentures of the Company and its associated corporations" above, at no time since incorporation of the Company were right to acquire benefits by means of the acquisition of shares in or debentures of the Company or of any other body corporate granted to any directors or their respective spouses or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company or any of its subsidiaries a party to any arrangement to enable the directors' their respective spouse or children under 18 years of age to acquire such rights in any other body corporate.

SHARE OPTION SCHEME

On 24 September 2013, the Company adopted a share option scheme (the “**Share Option Scheme**”) whereby the Board can grant options for the subscription of our shares to the employees, managerial staff and senior employees and those other persons that the Board considers that they will contribute or have contributed to the Group (the “**Participants**”) as described in the Share Option Scheme in order to serve as compliment and to reciprocate their contribution to the Group. The maximum number of shares that can be issued according to the Share Option Scheme was 64,840,530 shares, which is equivalent to 10% of the issued capital of the Company after completion of the Listing on the Stock Exchange. The number of options that may be granted pursuant to the terms of the Share Option Scheme shall not exceed 10% of the issued shares immediately after the completion of the Listing. Unless otherwise approved by the shareholders of the Company in general meeting, the number of shares that may be granted to a Participant under the options shall not exceed 1% within any 12-month period (other than those granted to the substantial shareholders (as defined in the Listing Rules) of the Company or the independent non-executive Directors or any of their respective associates (as defined in the Listing Rules)), or the total number of shares that may be granted under the options to the substantial shareholders of the Company or the independent non-executive Directors or any of their respective associates shall not exceed 0.1% of the shares in issue of the Company from time to time. There is no minimum period that the options must be held before they become exercisable, and the options granted shall be exercised within the period decided by the Board; however no options shall be exercised 10 years after they have been granted. The exercise price of the option shall be the higher of (a) the closing price of the shares on the daily quotation sheet of the Stock Exchange on the date of grant; (b) the average closing price of the shares on the daily quotation sheet of the Stock Exchange for the five trading days immediately preceding the date of grant; and (c) nominal value of the share. Each grantee shall pay a consideration of HK\$1.00 at the time the option is granted. The Share Option Scheme shall take effect from the date it is adopted and shall remain effective within a period of 10 years from that date.

Since the Share Option Scheme was adopted, no options have been granted up to the date of this quarterly report.

PURCHASE, SALES OR REDEMPTION OF THE COMPANY'S LISTED SHARES

During the three months ended 30 June 2014, there were no purchases, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's Articles of Association or the laws of Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to existing shareholders.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company had adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the required standard set out in the Model Code. The Company has made specific enquiry with all Directors and all the Directors have confirmed their compliance with the required standards set out in the Model Code throughout the period for the three months ended 30 June 2014.

CORPORATE GOVERNANCE PRACTICES

The Company strived to maintain a high standard of corporate governance and complied with the Corporate Governance Code set out in Appendix 14 to the Listing Rules. To the knowledge of the Board, the Company had fully complied with the code provisions in the Corporate Governance Code (the "**CG Code**") for the three months ended 30 June 2014 except for the following deviation from the code provisions:

The code provision A.2.1 of the CG Code prescribed, among others, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The roles of chairman and chief executive officer of the Company are not segregated and are exercised by the same individual. Mr. Weng Jiaxing serves as the chairman and chief executive officer. The Board believes that vesting the roles of the Chairman and the chief executive officer in the same person provides consistent and sustainable development of the Group, strong and consistent leadership in the Company's decision making and operational efficiency.

REMUNERATION COMMITTEE

The Remuneration Committee was established on 24 September 2013 in compliance with written terms of reference in compliance with Rule 3.25 of the Listing Rules. The Remuneration Committee consists of Mr. Chen Yong, an executive director of the Company and two independent non-executive directors, namely Mr. Wong Hon Kit and Dr. Liu Yongping. Mr. Wong Hon Kit is the Chairman of the Remuneration Committee.

The role and function of the Remuneration Committee include, but are not limited to, the determination of the specific remuneration package of all executive directors including benefits in kind, pension rights and compensation payments, including any compensation payable for loss or termination of their office or appointment, and making recommendations to the Board of the remuneration of non-executive directors. The Remuneration Committee considers factors such as salaries paid by comparable companies, time commitment and responsibilities of the directors, employment conditions elsewhere in the Group and desirability of performance-based remuneration.

NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

The Nomination and Corporate Governance Committee was established on 24 September 2013 in compliance with written terms of reference in compliance with paragraphs A.5.1 and D.3.1 of Appendix 14 to the Listing Rules. The Nomination and Corporate Governance Committee consists of Mr. Weng Jiaxing, an executive director of the Company and three independent non-executive directors, namely Mr. Liang Yichi, Mr. Wong Hon Kit and Dr. Lui Yongping. Mr. Weng Jiaxing is the Chairman of the Nomination and Corporate Governance Committee.

The primary duties of the Nomination and Corporate Governance Committee include, but are not limited to: (i) reviewing the structure, size and composition (including the skills, knowledge and experience) of our Board on a regular basis and making recommendations to our Board regarding any proposed changes; (ii) identifying individuals suitably qualified to become members of the Board and selecting or making recommendations to our Board on the selection of, individuals nominated for directorships; (iii) making recommendations to our Board on relevant matters relating to the appointment or re-appointment of Directors and succession planning for Directors in particular the chairman of our Board and the chief executive officer of our Company; and (iv) keeping the effectiveness of the corporate governance and system of internal controls of our Group.

AUDIT COMMITTEE

The Audit Committee was established on 24 September 2013 in compliance with written terms of reference in compliance with Rules 3.21 of the Listing Rules. The Audit Committee consists of three independent non-executive directors, namely Mr. Liang Yichi, Mr. Wong Hon Kit and Dr. Liu Yongping. Mr. Wong Hon Kit is the Chairman of the Audit Committee.

The primary duties of the Audit Committee include, but are not limited to: (i) to review and monitor the external auditors' independence and objectivity and the effectiveness of the audit process in accordance with applicable standard; (ii) monitoring integrity of financial statements of our Company and our Company's annual report and accounts, half-year report and, if prepared for publication, quarterly reports; (iii) reviewing our Company's financial controls, internal control and risk management systems; and (iv) reporting to our Board on the matters set out in the code provisions as stated in Appendix 14 to the Listing Rules.

The Group's unaudited condensed consolidated results for the three months ended 30 June 2014 were reviewed by the Audit Committee, which was of the opinion that the preparation of such results complied with the applicable accounting standards and requirements and that adequate disclosures were made.

By order of the Board
Wanjia Group Holdings Limited
Weng Jiaying
Chairman

Hong Kong, 13 August 2014